BNP Paribas increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,555 shares of the medical research company's stock after buying an additional 5,556 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.1% of BNP Paribas' investment portfolio, making the stock its 25th largest holding. BNP Paribas' holdings in Thermo Fisher Scientific were worth $26,815,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of the business. Alteri Wealth LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $358,000. Ancora Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 5.1% during the 4th quarter. Ancora Advisors LLC now owns 1,254 shares of the medical research company's stock worth $652,000 after purchasing an additional 61 shares during the period. Aptus Capital Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 13.8% in the 4th quarter. Aptus Capital Advisors LLC now owns 42,980 shares of the medical research company's stock valued at $22,361,000 after purchasing an additional 5,215 shares during the period. Aspire Growth Partners LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter valued at $219,000. Finally, AXA S.A. increased its holdings in Thermo Fisher Scientific by 5.7% in the fourth quarter. AXA S.A. now owns 648,421 shares of the medical research company's stock valued at $337,328,000 after buying an additional 34,741 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.
Thermo Fisher Scientific Stock Up 0.2 %
Shares of TMO traded up $0.77 during midday trading on Wednesday, hitting $407.79. The company had a trading volume of 2,959,388 shares, compared to its average volume of 1,788,786. Thermo Fisher Scientific Inc. has a 1 year low of $403.51 and a 1 year high of $627.88. The company's 50-day simple moving average is $471.62 and its 200-day simple moving average is $518.58. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a market capitalization of $153.94 billion, a P/E ratio of 24.67, a P/E/G ratio of 2.99 and a beta of 0.82.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period in the previous year, the company earned $5.11 EPS. The company's revenue for the quarter was up .2% on a year-over-year basis. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is currently 10.09%.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on TMO shares. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target for the company in a research note on Friday, January 10th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Citigroup decreased their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Scotiabank reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research report on Friday, April 25th. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $607.43.
Check Out Our Latest Research Report on TMO
Insider Activity
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock valued at $7,305,942 in the last ninety days. 0.33% of the stock is currently owned by company insiders.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
